9 November 2026
Eli Lilly's obesity pill cut sleep apnea severity in a year-long trial
Lilly says its daily GLP-1 pill Foundayo sharply reduced breathing interruptions during sleep in two late-stage studies, and it plans to seek FDA approval for sleep apnea by year-end.
Eli Lilly wants its weight-loss pill to do a second job. The company said on Monday that Foundayo, a once-a-day GLP-1 pill it launched in the US in April, made obstructive sleep apnea noticeably less severe in adults with obesity in a late-stage trial, and it plans to ask the FDA to approve it for that use by the end of the year.
What happened
Obstructive sleep apnea (OSA) is when the airway narrows or closes during sleep, so breathing keeps stopping and starting. It is linked to high blood pressure, heart failure and stroke. The usual fix is a PAP machine, a mask that pushes air in to keep the airway open, which many people find hard to live with.
Lilly ran two studies, each lasting 52 weeks. Researchers tracked the apnea-hypopnea index, a count of how many times per hour breathing is partly or fully blocked.
- In 363 people not using a PAP machine, Foundayo cut about 21.1 events per hour, versus 4.8 on a placebo (a dummy pill). That is a 43.8% drop against 6.3%, and 31.5% of the Foundayo group reached remission or mild OSA.
- In 349 people who kept using PAP, Foundayo cut about 18.3 events per hour, versus 5.5 on placebo, a 27.5% drop against 3%.
- Patients lost roughly 11% of their body weight on average across the groups.
Side effects were mostly stomach-related, such as nausea and diarrhea, and generally mild to moderate. Lilly said the safety results were in line with earlier Foundayo trials. About 12% of the non-PAP Foundayo group stopped the drug because of side effects, against 3.8% on placebo.
Why it matters
Lilly already has one drug cleared for sleep apnea: its injection Zepbound became the first medicine approved in the US for the condition in December 2024. A pill version would give patients an option without needles, and every new approved use widens the market a drug can be sold into. The National Council on Aging estimates about 80 million people aged 20 and over in the US have OSA, and Lilly says most people with the condition have never been diagnosed.
For scale, Lilly is valued at about $1.29 trillion on Noorult's latest data, with revenue of roughly $86 billion over the twelve months to September, much of it from its GLP-1 drugs. These are trial results reported by the company; the FDA has not yet reviewed them.
What to watch
- Lilly's filing with the FDA, which it says will come by the end of 2026.
- Full trial data, typically presented at a medical meeting or in a journal.
- Competing GLP-1 treatments, several of which have also shown promise in sleep apnea.
Lilly's financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion